Newspaper publication of Unaudited Financial Results for the quarter and half year ended September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Drugs Ltd has submitted to BSE copies of the newspaper advertisements of its unaudited financial results for the quarter and half year ended September 30, 2025, published on November 15, 2025 in Business Standard (all editions) and Andhra Prabha (Hyderabad edition). For Q2 FY26, standalone revenue from operations stood at Rs 27.28 crore versus Rs 26.10 crore in Q2 FY25, a modest ~4.5% rise, while net profit after exceptional items dipped to Rs 1.00 crore from Rs 1.09 crore. On a half-year basis, revenue declined to Rs 51.11 crore from Rs 59.07 crore (~13.5% lower) and net profit fell to Rs 2.04 crore from Rs 2.72 crore (~25% lower). Basic EPS for H1 FY26 came in at Rs 2.71 versus Rs 3.61 in H1 FY25. The filing is made under Regulation 30 and 47 of SEBI LODR, 2015, with the full results also available on the company's website.
This is a procedural disclosure of already-filed quarterly results, so there is no new catalyst for the stock. However, the underlying numbers indicate weak H1 performance with both revenue and profit declining year-on-year, which shareholders should track against peers and prior trends.